Accretion Nutraveda (BOM:544694) Total Equity: ₹354.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544694 Accretion Nutraveda Ltd BOM:544694
21 GF Score
Price ₹283.95
! 3 Warning Signs
View Full Analysis

What is Accretion Nutraveda Total Equity?

Accretion Nutraveda BOM:544694 21 Total Equity is ₹354.7 Mil as of Mar. 2026. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review.

Accretion Nutraveda's total equity for the quarter that ended in Mar. 2026 was ₹354.7 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Accretion Nutraveda Total Equity Historical Data

* Premium members only.

The historical data trend for Accretion Nutraveda's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Accretion Nutraveda Total Equity Chart

Accretion Nutraveda Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Equity
2.63 10.85 53.49 354.73

Accretion Nutraveda Semi-Annual Data
Mar23 Mar24 Mar25 Sep25 Mar26
Total Equity 2.63 10.85 53.49 82.67 354.73
BOM:544694
21GF Score
Accretion Nutraveda Ltd BOM:544694
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Accretion Nutraveda Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Accretion Nutraveda's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=417.938-63.206
=354.7

Accretion Nutraveda's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=417.938-63.206
=354.7

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹354.7 Mil mean?
Accretion Nutraveda (BOM:544694) has a Total Equity of ₹354.7 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Accretion Nutraveda and its competitors.
Is Accretion Nutraveda's Total Equity too high?
Accretion Nutraveda's current Total Equity is ₹354.7 Mil. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Total Equity compare to ZTS?
Accretion Nutraveda's Total Equity of ₹354.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Accretion Nutraveda and its competitors. Accretion Nutraveda's current Total Equity is ₹354.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Total Equity of ₹354.7 Mil. The current Total Equity is ₹354.7 Mil. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Total Equity is ₹354.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accretion Nutraveda Business Description

Address 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, Taluka Sanand, Ahmedabad, GJ, IND, 382213
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score

Get the complete analysis for BOM:544694

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹283.95
Price